Kura Oncology, Inc.

NASDAQ:KURA

Biotechnology

Healthcare
$7.34 +0.73%

+$0.07 today

Market cap
$674.39M
Beta
0.36
P/E (TTM)
-2.9
EPS (TTM)
-$3.32
52W Low $5.45High $12.49

Volume 2.46M

Average 1.66M

KURA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Kura Oncology, Inc.NASDAQ: KURA

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 88.61M shares rose 1.4% year over year, in line with the +1.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +9.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1.4% holds above the trailing-twelve-month pace of +1.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
88.61M+0.6% QoQ
Last fiscal yearDec 2025
87.68M+1.8% YoY
LTMMar 2026
87.97M+1.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.4%——
1 year+1.8%——
3-year CAGR+9.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
87.68M USD
Year-over-year change
+1.8%
4-year CAGR
+7.2%

Weighted Avg Shares (Diluted) vs competitors

How KURA compares with its peers on the latest reported figures

  • KURA's LTM Mar 2026 weighted avg shares (diluted) of 87.97M shares is the 5th highest of the 11 companies compared; the peer median is 84.49M shares.
  • Its year-over-year change of +1.1% is the lowest of 11, against a peer median of +28.2%.
  • Over three fiscal years its annual growth of +9.4% compares with a peer median of +15.1%.
KURA Competitors Peer median
Weighted Avg Shares (Diluted) for KURA and competitors
Company Period LTM YoY 3-year CAGR
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026179.3M +94.5%+77.8%
HCMHUTCHMED (China) LimitedLTM Jun 2025174.57M +1.2%+1.0%
NRIXNurix Therapeutics, Inc.LTM Aug 2026108.1M +31.0%+21.3%
ORICORIC Pharmaceuticals, Inc.LTM Mar 202692.59M +31.1%+30.3%
KURAKura Oncology, Inc.LTM Mar 202687.97M +1.1%+9.4%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 202686.55M +1.2%+12.5%
VSTMVerastem, Inc.LTM Mar 202682.44M +107.0%+62.5%
CRDFCardiff Oncology, Inc.LTM Mar 202667.15M +43.6%+15.3%
TYRATyra Biosciences, Inc.LTM Mar 202660.14M +2.0%+12.5%
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 202627.33M +25.4%+15.0%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.96M +6.3%+3.0%
Peer median (excluding KURA) 84.49M+28.2%+15.1%

Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00053.88M67.48M
Cost of Revenue00849K057K
Gross Profit00(849K)53.88M67.43M
Gross Margin———100.0%99.9%
Research & Development84.72M92.81M115.24M169.97M251.07M
Selling, General & Admin46.54M47.05M50.57M77.11M119.98M
Operating Expenses131.26M139.87M164.96M247.08M371.06M
Depreciation & Amortization558K759K849K848K1.03M
EBITDA(129.49M)(134.85M)(150.23M)(169.5M)(275.83M)
EBITDA Margin———-314.6%-408.7%
Operating Income(131.26M)(139.87M)(165.8M)(193.2M)(303.63M)
Operating Margin———-358.5%-449.9%
Interest Income1.21M4.25M14.72M22.85M26.77M
Interest Expense414K229K1.55M1.62M1.51M
Other Income / Expenses792K4.03M13.17M21.23M25.26M
Income Before Tax(130.47M)(135.84M)(152.63M)(171.97M)(278.37M)
Pre-Tax Margin———-319.1%-412.5%
Income Tax Expense0002.02M297K
Net Income(130.47M)(135.84M)(152.63M)(173.98M)(278.67M)
Net Margin———-322.9%-412.9%
EPS (Basic)(1.97)(2.03)(2.08)(2.02)(3.18)
EPS (Diluted)(1.97)(2.03)(2.08)(2.02)(3.18)
Weighted Avg Shares66.35M66.99M73.23M86.16M87.68M
Weighted Avg Shares (Diluted)66.35M66.99M73.23M86.16M87.68M

Kura Oncology, Inc.

NASDAQ:KURA

Intrinsic Alpha fair value

Locked

Current Price

$7.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.